caa a22 4500 386389608 CHVBK 20180307112110.0 cr unu---uuuuu 161130s1989 xx s 000 0 eng 10.1017/S0269727000010691 doi S0269727000010691 pii (NATIONALLICENCE)cambridge-10.1017/S0269727000010691 Current controversies in the role of antioestrogens in the treatment of carcinoma of the breast [Elektronische Daten] The development of the triphenylethylene derivatives has been a major advance in the treatment of breast carcinoma, due to their low toxicity. Currently there is controversy not only about their mode of action but in three main areas of clinical practice: (A) adjuvant therapy in premenopausal and oestrogen receptor-negative cases; (B) primary therapy in the elderly; (C) the prevention of breast cancer. The United States' National Institute of Health consensus of 1985 that adjuvant tamoxifen be confined to postmenopausal women with positive nodes and ER positive tumours has been refuted by randomised clinical trials. The evidence that ER negative tumours also respond to tamoxifen has added to laboratory evidence that tamoxifen acts other than purely by oestrogen antagonism at the ER. The use of tamoxifen as sole treatment in primary breast cancer in the elderly is being evaluated in randomised clinical trials. Two that have been reported so far have flaws which make their contradictory conclusions difficult to assess. Recent results from the CRC trial suggest that tamoxifen has more benefit than simply preventing cancer deaths and clarification of the effects of triphenylethylenes on bone metabolism and the cardiovascular system may strengthen the case for a trial of prophylactic tamoxifen in those at risk of developing breast carcinoma. Copyright © Royal Society of Edinburgh 1989 Oestrogen Deprivation - Antioestrogens nationallicence Baum M. Department of Surgery, Rayne Institute, King's College Hospital School of Medicine and Dentistry, 123 Coldharbour Lane, London SE5 9NU, U.K. Fraser S. C. A. Department of Surgery, Rayne Institute, King's College Hospital School of Medicine and Dentistry, 123 Coldharbour Lane, London SE5 9NU, U.K. Colletta A. A. Department of Surgery, Rayne Institute, King's College Hospital School of Medicine and Dentistry, 123 Coldharbour Lane, London SE5 9NU, U.K. Ebbs S. R. Department of Surgery, Rayne Institute, King's College Hospital School of Medicine and Dentistry, 123 Coldharbour Lane, London SE5 9NU, U.K. Proceedings of the Royal Society of Edinburgh. Section B. Biological Sciences Royal Society of Edinburgh Scotland Foundation 95(1989), 221-229 0269-7270 95<221 1989 95 PRB https://doi.org/10.1017/S0269727000010691 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1017/S0269727000010691 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Baum M. Department of Surgery, Rayne Institute, King's College Hospital School of Medicine and Dentistry, 123 Coldharbour Lane, London SE5 9NU, U.K NATIONALLICENCE 700 1- Fraser S. C. A. Department of Surgery, Rayne Institute, King's College Hospital School of Medicine and Dentistry, 123 Coldharbour Lane, London SE5 9NU, U.K NATIONALLICENCE 700 1- Colletta A. A. Department of Surgery, Rayne Institute, King's College Hospital School of Medicine and Dentistry, 123 Coldharbour Lane, London SE5 9NU, U.K NATIONALLICENCE 700 1- Ebbs S. R. Department of Surgery, Rayne Institute, King's College Hospital School of Medicine and Dentistry, 123 Coldharbour Lane, London SE5 9NU, U.K NATIONALLICENCE 773 0- Proceedings of the Royal Society of Edinburgh. Section B. Biological Sciences Royal Society of Edinburgh Scotland Foundation 95(1989), 221-229 0269-7270 95<221 1989 95 PRB CC0 http://creativecommons.org/publicdomain/zero/1.0 nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-cambridge